spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Novasep Announces Major Recapitalisation to Boost its Growth

Novasep

A strongly improved balance sheet, new shareholders and entrepreneurial management to support the group’s development going forward

Novasep, a leading provider of purification-based manufacturing solutions for lifescience molecules, today announces that it has completed its previously-announced process to strengthen its balance sheet and increase its funds available for investment in customer-focused growth initiatives.  
 
Novasep’s approximately EUR 310 million recapitalization includes EUR 30 million of new capital invested by the Fonds Stratégique d'Investissement (FSI), France’s strategic investment fund, which has become a shareholder in Novasep. Azulis, a French investment fund and historical investor of Novasep, also invested EUR three million in equity. As a result, Novasep currently has more than EUR 40 million in cash available for financing growth projects. Moreover, the recapitalization significantly reduces Novasep’s annual interest expense, enabling it to further grow its cash available for investment going forward.
 
In addition to Roger-Marc Nicoud, founder and CEO of Novasep, Novasep’s board also includes Bernard Dubois, former head of Sanofi Aventis’ global industrial operations, Hugues Lecat, CEO and chairman of the management board of the pharmaceutical company Ethypharm, Thomas Devedjan, member of the FSI executive committee, and representatives of the company’s international institutional shareholders.  
 
Roger-Marc Nicoud commented: “I am proud and delighted that we have completed this major transaction and earned the support of the FSI. This is an important endorsement of Novasep's unique business model, which leverages Novasep’s expertise in purification to enable our customers to either insource or outsource to us the production of their active molecules.

"Moreover, these accomplishments have positioned our company for strong growth again now that the refinancing is complete. Novasep can and will now move forward to develop ever more innovative and competitive solutions that will make Novasep an even more valuable partner to our current customers as well as to new customers. I believe this is the best and most important way for Novasep to express our deep appreciation for the continued confidence of our customers, employees and financial stakeholders."
 
Bernard Dubois commented: “I have known Novasep for many years and I am very pleased to contribute to the company’s development and growth, leveraging my experience from the customer perspective.”
 
Thomas Devedjan, member of the FSI executive committee, affirmed: "We are very happy about the recapitalization of Novasep, which significantly strengthens the company's financial structure and, combined with our contribution of EUR 30 million in new capital, will enable the company to pursue its strategy and develop its leading position in purification technologies."

As expected, in addition to the FSI, Novasep shares are now held by a group of international institutional shareholders who have been long-term supporters of the company and holders of company’s securities. The management team has partnered with the new owner group and has received a significant financial stake in the company.
phone +33 3 83 49 71 00
email Novasep@novasep.com
web www.novasep.com
email 81 Boulevard de la Moselle, 54340 Pompey, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit

Raleigh, N.C., Oct. 2, 2014 - INC Research, a leading, global Phase I to IV clinical research organization (CRO), today announced plans for an extensive presence at the 2014 Society for Clinical Research Sites (SCRS) Site Solutions Summit taking place Oct. 10-12, 2014, on Amelia Island, Fla. Recognizing the critical role clinical research sites play in bringing new medicines to market for patients, the Company will be maximizing the opportunities available at the SCRS Summit to deepen its connections with this important stakeholder group and contribute to the ongoing dialogue on how CROs and sites can work more effectively together for the benefit of sponsors and patients.
More info >>


White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

Industry Events

BIO-Europe® 2014

3-5 November 2014, Frankfurt, Germany

BIO-Europe® is the preeminent partnering conference for the life sciences. BIO-Europe brings together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop and panel participation, a high profile exhibition, and private, prescheduled one-to-one meetings.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement